• Explore /
  • Poster
  • / Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.

Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.

Abstract Poster

Authors

Carol Aghajanian

Carol Aghajanian

Memorial Sloan Kettering Cancer Center, New York, NY

Carol Aghajanian , Robert L. Coleman , Amit M. Oza , Domenica Lorusso , Ana Oaknin , Andrew Peter Dean , Nicoletta Colombo , Johanne I Weberpals , Andrew R. Clamp , Giovanni Scambia , Alexandra Leary , Robert W. Holloway , Peter C.C. Fong , Jeffrey C. Goh , David M. O'Malley , Susana N. Banerjee , Kenton Wride , Teresa Cameron , Jonathan A. Ledermann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01968213

Citation

J Clin Oncol 36, 2018 (suppl; abstr 5537)

DOI

10.1200/JCO.2018.36.15_suppl.5537

Abstract #

5537

Poster Bd #

264

Abstract Disclosures

Similar Posters

First Author: Robert L. Coleman

First Author: Ana Oaknin

First Author: Robert L. Coleman

First Author: Sumitra Ananda